On July 7, Protagonist Therapeutics rose 6.35% in regular trading, trading at $139.975/share, with turnover of $117 million. The rally was driven by investment bank Truist significantly raising its price target on the stock from $121 to $145, while maintaining a Buy rating.

The nearly 20% target price increase is notably above the current analyst consensus. According to FactSet, the average analyst rating on Protagonist Therapeutics is Buy, with a mean price target of $119.15 — well below Truist's updated $145 target. This marks Truist's second target price raise in recent months, having previously lifted its target from $110 to $121 in April. The widening gap between Truist's outlook and the broader Street consensus may serve as a near-term positive catalyst for the stock.

Protagonist Therapeutics is a biopharmaceutical company developing peptide-based drugs for hematology, blood disorders, and inflammatory diseases. Its lead asset Rusfertide, an injectable hepcidin mimetic for polycythemia vera, is partnered with Takeda for commercialization.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)